Showing results (71-80 of 135) with videos related to
Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2021
Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAF -Driven Papillary Thyroid Cancer PatientsTheodora Pappa, Sara Ahmadi, Ellen Marqusee, et al.Archives of Pathology & Laboratory Medicine|July 25, 2022
Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System TumorsShakti H Ramkissoon, Helen Fernandes, Dolores H Lopez-Terrada, et al.Neuro-Oncology|March 25, 2017
Leveraging molecular datasets for biomarker-based clinical trial design in glioblastomaShyam K Tanguturi, Lorenzo Trippa, Shakti H Ramkissoon, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2016
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the LungDavid H Hwang, Lynette M Sholl, Vanesa Rojas-Rudilla, et al.Cold Spring Harbor Molecular Case Studies|June 2, 2021
Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosisPanieh Terraf, Lynette M Sholl, Matthew S Davids, et al.Nucleic Acids Research|November 28, 2014
BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmersRyan P Abo, Matthew Ducar, Elizabeth P Garcia, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 12, 2016
Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CAJaclyn C Watkins, Brooke E Howitt, Neil S Horowitz, et al.Archives of Pathology & Laboratory Medicine|March 19, 2026
Factors Influencing Choice of Laboratory-Developed Tests and US Food and Drug Administration (FDA)-Approved or FDA-Cleared In Vitro Diagnostics for Molecular AnalytesBenjamin F Smith, Julia A Bridge, Susan J Hsiao, et al.Neuro-Oncology|September 7, 2018
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challengesAlireza Mansouri, Laureen D Hachem, Sheila Mansouri, et al.Archives of Pathology & Laboratory Medicine|October 14, 2017
A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing PracticesRakesh Nagarajan, Angela N Bartley, Julia A Bridge, et al.Pageof 14